Serotonergic and noradrenergic markers of post-traumatic stress disorder with and without major depression.
Some studies have suggested that disorders in the peripheral and central metabolism of serotonin (5-HT) and noradrenaline (NE) may play roles in the pathophysiology of post-traumatic stress disorder (PTSD). This study examines (1) the availability of plasma total tryptophan, the precursor of 5-HT, and tyrosine, the precursor of NE; and (2) the platelet 5-HT transporter and alpha 2-adrenoceptor (alpha 2-AR) binding sites in patients with PTSD and healthy volunteers. High-performance liquid chromatography (HPLC) was employed to measure plasma tryptophan and tyrosine as well as amino acids known to compete with the same cerebral transport system; that is, valine, leucine, phenylalanine, and isoleucine. The maximum number of binding sites (Bmax) and their affinity (Kd) for binding to [3H]-paroxetine and [3H]-rauwolscine, a selective alpha 2-AR antagonist, were determined. [3H]-paroxetine and [3H]-rauwolscine binding Kd values were significantly higher in patients with PTSD than in healthy volunteers. [3H]-rauwolscine binding Kd values were significantly higher in patients with PTSD and concurrent major depression (MD) than in PTSD patients without MD and healthy volunteers. Plasma tyrosine concentrations and the ratio of tyrosine/valine + leucine + isoleucine + phenylalanine + tryptophan were significantly higher in PTSD patients with MD than in those without MD and healthy volunteers. The results show that PTSD is accompanied by lower affinity of paroxetine binding sites and that PTSD with concurrent MD is accompanied by lower affinity of alpha 2-ARs and increased plasma tyrosine availability to the brain. The results suggest that (1) serotonergic mechanisms, such as defects in the 5-HT transporter system, may play a role in the pathophysiology of PTSD; and (2) that catecholaminergic mechanisms, such as increased precursor availability and lowered affinity of alpha 2-ARs, may play a role in the pathophysiology of PTSD with concurrent MD.
Maes
M
M
Clinical Research Center for Mental Health, Antwerp, Belgium.
Lin
A H
AH
Verkerk
R
R
Delmeire
L
L
Van Gastel
A
A
Van der Planken
M
M
Scharpé
S
S
D000317:Adrenergic alpha-Antagonists / Q000097:blood; D000328:Adult; D015415:Biomarkers; D001792:Blood Platelets / Q000378:metabolism; D003866:Depressive Disorder / Q000097:blood* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000502:physiology*; D017374:Paroxetine / Q000097:blood / Q000493:pharmacokinetics; D012701:Serotonin / Q000502:physiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000097:blood / Q000493:pharmacokinetics; D013313:Stress Disorders, Post-Traumatic / Q000097:blood* / Q000523:psychology; D014443:Tyrosine / Q000097:blood; D015016:Yohimbine / Q000097:blood
D000317:Adrenergic alpha-Antagonists; D015415:Biomarkers; D009638:Norepinephrine; D017374:Paroxetine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D014443:Tyrosine; D015016:Yohimbine